High serum concentrations of procalcitonin, a stable 116-amino acid precursor molecule to the proteohormone calcitonin, have been reported in patients with severe systemic bacterial or fungal, but not viral, infections (1, 2 ) . Serum procalcitonin concentrations correlated with the severity of bacterial infection and with the clinical course of the patients (3 ) . In healthy volunteers, serum procalcitonin is barely detectable; however, it increases consistently after endotoxin injection (4 ) . Therefore, serum procalcitonin is regarded by many authors as a useful marker of the presence, course, and prognosis of bacterial infection.
To date we are aware of three reports describing the value of procalcitonin for diagnosis of neonatal infection (1, 5, 6 ) . The reports agree that patients with bacterial invasion have high concentrations of serum procalcitonin. However, there are some discrepancies regarding the procalcitonin concentrations in sera of newborn infants without bacterial infection.
In our study, procalcitonin concentrations were examined in 122 serum samples of 75 newborn infants. Neonates were included if surplus sample (20 L) was available after routine determination of serum C-reactive protein (CRP); the study was conducted in accordance with the Helsinki Declaration of 1975/1983. Requests for routine CRP measurements were made by the neonatal ward of Oststadtkrankenhaus Hannover, according to the usual diagnostic protocol. This protocol includes analysis of serum CRP only in infants at increased risk of infection (premature rupture of membranes more than 12 h before delivery, discoloring of amniotic fluid, or clinical signs of maternal or neonatal infection). Thirteen infants received antibiotic treatment; the 22 samples obtained from these infants were excluded from further analysis. Blood was obtained from heel puncture; the sampling time was recorded diligently. If procalcitonin quantitation was not done the same day, the serum was stored at Ϫ20°C. Procalcitonin was determined by an immunoluminometric assay (Lumitest ® PCT, Brahms Diagnostica GmbH). For statistical comparisons, the Mann-Whitney test was used. In the study period, interassay CVs at low (Ϸ1.3 g/L) and high (Ϸ59 g/L) procalcitonin concentrations were Ͻ10% and Ͻ8%, respectively.
Serum procalcitonin concentration was clearly related to the age of the infant (Table 1 ). In neonates Ͻ12 h of age, markedly increased procalcitonin concentrations (defined as Ͼ2 g/L) were rarely observed; of 26 samples, only one, drawn 11 h after birth, showed a value of 3.8 g/L. In contrast, procalcitonin Ͼ2 g/L was found in a substantial proportion of samples obtained 12-47 h after birth. The highest values observed during 12-h periods were: 22.5, 8.6, and 5.7 g/L at 12-23 h after birth; 11.7, 6.0, and 5.3 g/L at 24 -35 h; and 7.7 and 3.7 g/L at 36 -47 h. Mean procalcitonin peaked between 24 and 35 h after birth; the increase was highly significant (12-23 h vs 0 -12 h, P Ͻ0.001; 24 -35 h vs 12-23 h, P Ͻ0.05). Procalcitonin concentrations tended to decrease afterwards; the difference between the time periods 12-23 h and Ն48 h after birth was significant (P Ͻ0.001). Procalcitonin was clearly increased (2.4 g/L) in one sample obtained more than 48 h after birth.
Individual variations of serum procalcitonin concentrations were examined in 22 healthy neonates without antibiotic treatment. The general trends were uniformly reflected in individual time courses; serum procalcitonin always increased in the first 24 h after birth and always decreased in infants more than 36 h of age. In three infants, pronounced increases of procalcitonin concentrations (Ն5 g/L) were observed in the first 36 h after birth.
There are conflicting data regarding serum procalcitonin in neonates without infection. Although procalcitonin concentrations Ͼ1 g/L were not observed in the control neonates in two studies (1, 5 ) , concentrations up to 15 g/L were measured by other investigators at day 1 after birth (6 ) . Our data confirm the latter findings and give a more detailed picture of the time course of serum procalcitonin in infants without infection. We studied neonates at increased risk of infection because we think that these patients represent the most relevant group for differential diagnosis of overt infection. We cannot rule out subclinical infection in some of our infants; however, it should be noted that none of them developed a significant increase of serum CRP, and they did well without antibiotic treatment.
Our data suggest that procalcitonin concentrations peak between 24 and 36 h after birth; in this time period, markedly increased concentrations as well as clear in- Reverse transcription-PCR (RT-PCR), combined with an endogenous and exogenous standard, is used extensively to quantify specific mRNAs, but few studies have evaluated the reproducibility of these assays (1-7) . Increased expression of the epidermal growth factor receptor (EGFr) has been observed in several human cancers and has been suggested to predict tumor progression (8 -11). Quantitative analysis for the EGFr mRNA using competitive RT-PCR has been described (12-14) , but the analytical imprecision has not yet been documented systematically.
A primer pair was designed to flank the first intron of the human EGFr gene (15, 16) . The 350-bp cDNA fragment was amplified as described below, using the following primers: primer I (5Ј-GAC CCT CCG GGA CGG-3Ј), spanning positions 191-205; and primer II (5Ј-GGC ATA GGA ATT TTC GTA GTA CAT AT-3Ј), spanning positions 515-540 and cloned into a pCR TM II vector (TA Cloning System, Invitrogen). The "EGFr" plasmid was purified using a Qiagen plasmid midi kit (Qiagen, Inc.) and cleaved by BglII (Pharmacia Biotech). A 69-bp deletion was obtained by PCR (see below) using the linear plasmid as template, primer III (5Ј-GAC CCT CCG GGA CGG CCG GGC AAG GCA CGA GTA ACA AGC TCA CGC AGT TGG 3Ј), and primer II (Fig. 1A) . The PCR product was cloned into a pCR II vector, purified, and cleaved as above. The PCR products of the EGFr and standard were sequenced on both strands, confirming their identity and the absence of PCR errors (data not shown).
To synthesize the RNA standard, 5 g of the linear plasmid (containing the 69-bp deletion) was incubated with 100 units of SP6 RNA polymerase according to the manufacturer's protocol (Promega Corp.). Fifty microliters of 25 mmol/L MgCl 2 was added to the mixture before treatment with 20 U of RNase-free DNase I (Promega) for 30 min at 37°C. The RNA standard was extracted using 1 volume of phenol:chloroform and centrifuged at 13 000g for 15 min at 4°C. The aqueous phase was mixed with 1 volume of chloroform:isoamyl alcohol (49:1, by volume) and centrifuged as above. One volume of ethanol and 0.5 volume of 7.5 mol/L ammonium acetate were added to the aqueous phase. Precipitation was performed for 30 min at Ϫ80°C, followed by centrifugation at 13 000g for 15 min at 4°C. The pellet was resuspended in 40 L of diethyl pyrocarbonate-treated double-distilled water (DEPC ddH 2 O). PCR was performed before and after the reverse transcriptase step. RNA concentration was determined by using an ultraviolet spectrophotometer (with absorbance at 260 nm of 1 corresponding to RNA ϭ 40 mg/L) (17). RNA standards (3.7 ϫ 10 Ϫ8 and 3.7 ϫ 10 Ϫ12 mol/L) were stored in small aliquots at Ϫ150°C and thawed a maximum of four times before disposal. Human biopsies were obtained immediately after delivery from 12 healthy placentae in accordance with the Helsinki Declaration. From each placenta, four biopsies were removed, frozen immediately in liquid nitrogen, and stored at Ϫ150°C.
EGFr protein was determined using an ELISA technique (18). Protein analysis was performed using a microtiter assay (BCA protein assay reagent, Pierce).
Total RNA was extracted from 20 mg of placenta by adding 800 L of a denaturing solution (solution D: 4 mol/L guanidine thiocyanate, 25 mmol/L sodium citrate, pH 7, 5 g/L sacrosyl, and 0.1 mmol/L 2-mercaptoethanol) and homogenized with a "turbo mixer" (Heidolph Diax 600) (19). The RNA pellet was resuspended in 25-40 L DEPC ddH 2 O and stored at Ϫ150°C. RNA (1:50 dilution in DEPC ddH 2 O) was quantified with use of an ultraviolet spectrophotometer (as above). For the imprecision experiments, RNAs from each placenta biopsy were pooled, and 20 aliquots were stored at Ϫ150°C.
The reverse transcriptase reaction was performed as described in the manufacturer's protocol (Clontech 1 st. strand TM cDNA synthesis kit). Total RNA (0.5 g) was converted to cDNA by priming with random hexamer primer (1 mol/L) and MMLV reverse transcriptase (200 U/g RNA) in a total volume of 20 L. A 1:10 dilution was performed, and 10 L cDNA was added to the PCR buffer containing 1ϫ reaction buffer [10 mmol/L Tris-HCl (pH 9.0), 50 mmol/L KCl, 1.5 mmol/L MgCl 2 , and 0.01 g/L gelatin], 100 mol/L deoxynucleotide triphosphates, 24.8 pmol primer I, 12.8 pmol primer II, and 1.0 U Taq DNA polymerase in a final volume of 50 L (Pharmacia Biotech).
